Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized parallel trial of escitalopram versus reboxetine on somatic and visceral sensitivity in major depressive disorder
2004-001900-12Phase 2Active
- Sponsor
- Vall d'Hebron University Hospital
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of escitalopram and norethindrone in major depressive disorder (MDD) (3 arms), sponsored by Vall d'Hebron University Hospital. Primary endpoint: Major depressive disorder symptom assessment. Started Sep 2004; status: active.
02
Drugs
escitalopramnorethindrone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2004-001900-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001900-12.